VERTEX PHARMACEUTICALS INC / MA (VRTX)
As-reported financials and SEC filings for VERTEX PHARMACEUTICALS INC / MA. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals is a global biotechnology company that develops and commercializes medicines for serious diseases, focusing on specialty markets. Its approved products treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company serves patients worldwide and advances clinical programs for additional diseases including kidney disorders, neuropathic pain, and type 1 diabetes.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Vertex Pharmaceuticals Inc / Ma
- Revenue grew 8.9% to $12.0B in FY2025, slower than the 11.7% the year before.
- Operating margin is 34.8% in FY2025, -2.0 pp against 36.7% in FY2021.
- Most recent quarter Q2 FY2026: revenue $3.3B, up 12.5% from Q2 FY2025.
- Free cash flow was $3.2B in FY2025, 26.6% of revenue.
- Net income turned positive at $4.0B in FY2025, from a $536M loss in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Vertex Pharmaceuticals Inc / Ma’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Vertex Pharmaceuticals Inc / Ma’s operating margin of 34.8% ranks in the 95th percentile of the 113 pharmaceutical companies reporting it. Vertex Pharmaceuticals Inc / Ma’s gross margin of 86.2% ranks in the 90th percentile of the 69 pharmaceutical companies reporting it. Vertex Pharmaceuticals Inc / Ma’s net margin of 32.9% ranks in the 88th percentile of the 122 pharmaceutical companies reporting it.
No reported insider purchases (code P) in the last 90 days; 6 insider sales totaling $4.6M. For context, about 14% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 2 of the superinvestors we track (plus 7 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| AQR Capital Managementquant | Q2 2026 | $305.0M | 616.2K | Added |
| Citadel Advisorsquant | Q2 2026 | $253.5M | 510.4K | Added |
| Millennium Managementquant | Q2 2026 | $232.7M | 468.4K | Added |
| Renaissance Technologiesquant | Q2 2026 | $159.0M | 320.0K | Reduced |
| Two Sigma Investmentsquant | Q2 2026 | $141.6M | 285.0K | Reduced |
| Gotham Asset Management | Q2 2026 | $9.4M | 19.0K | Reduced |
| Bridgewater Associates | Q2 2026 | $5.4M | 10.9K | Reduced |
| D. E. Shawquant | Q2 2026 | $1.5M | 3.1K | Reduced |
| Point72 Asset Managementquant | Q2 2026 | $1.3M | 2.6K | New |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-07-02 filed 2026-07-07 | McKechnie DuncanEVP, Chief Commercial Officer | Sell | 1.5K | $519.00 | $800K |
2026-07-02 filed 2026-07-07 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Sell | 1.5K | $524.99 | $787K |
2026-07-01 filed 2026-07-06 | Liu JoyEVP and Chief Legal Officer | Sell | 828 | $502.71 | $416K |
2026-06-26 filed 2026-06-30 | Bozic CarmenEVP and CMO | Sell | 596 | $482.50 | $288K |
2026-06-18 filed 2026-06-23 | Bozic CarmenEVP and CMO | Sell | 1.0K | $462.17 | $471K |
2026-06-15 filed 2026-06-17 | Bozic CarmenEVP and CMO | Sell | 4.1K | $450.00 | $1.8M |
2026-06-05 filed 2026-06-09 | Bozic CarmenEVP and CMO | Sell | 1.7K | $450.00 | $785K |
2026-06-01 filed 2026-06-03 | Liu JoyEVP and Chief Legal Officer | Sell | 828 | $439.91 | $364K |
2026-05-29 filed 2026-06-02 | Bozic CarmenEVP and CMO | Sell | 2.0K | $450.00 | $888K |
2026-05-15 filed 2026-05-19 | Bozic CarmenEVP and CMO | Sell | 1.4K | $453.45 | $614K |
2026-05-15 filed 2026-05-19 | Bunnage Mark E.EVP, Chief Scientific Officer | Sell | 33 | $453.45 | $15K |
2026-05-12 filed 2026-05-14 | Bozic CarmenEVP and CMO | Sell | 7.0K | $450.00 | $3.1M |
Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-31 | 4.7M | +12.4% | 4.51 |
| 2026-08-14 | 4.1M | +5.2% | 3.09 |
| 2026-07-31 | 3.9M | -20.9% | 2.99 |
| 2026-07-15 | 5.0M | +1.0% | 3.10 |
| 2026-06-30 | 4.9M | +7.0% | 2.01 |
| 2026-06-15 | 4.6M | +2.8% | 3.82 |
| 2026-05-29 | 4.5M | +0.7% | 3.19 |
| 2026-05-15 | 4.5M | +6.9% | 3.64 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B |
| Operating income | $4.17B | $-232.9M | $3.83B | $4.31B | $2.78B |
| Net income | $3.95B | $-535.6M | $3.62B | $3.32B | $2.34B |
| Diluted EPS | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B |
| Current assets | $11.20B | $9.60B | $14.14B | $13.23B | $9.56B |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B |
| Current liabilities | $3.86B | $3.56B | $3.55B | $2.74B | $2.14B |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Total equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $3.63B | $-492.6M | $3.54B | $4.13B | $2.64B |
| Capital expenditure | $437.6M | $297.7M | $200.4M | $204.7M | $235.0M |
| Free cash flow | $3.19B | $-790.3M | $3.34B | $3.93B | $2.41B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | $3.33B | 12.5% | $1.10B | $4.31 |
| Q1 FY2026 | $2.99B | 7.8% | $1.03B | $4.02 |
| Q4 FY2025 | $3.19B | 9.5% | $1.19B | $4.65 |
| Q3 FY2025 | $3.08B | 11.0% | $1.08B | $4.20 |
| Q2 FY2025 | $2.96B | 12.1% | $1.03B | $3.99 |
| Q1 FY2025 | $2.77B | 3.0% | $646.3M | $2.49 |
| Q4 FY2024 | $2.91B | 15.7% | $913.0M | $3.55 |
| Q3 FY2024 | $2.77B | 11.6% | $1.05B | $4.01 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest pharmaceutical peers
VRTX head to head
Monitor VRTX
Get an alert when Vertex Pharmaceuticals Inc / Ma files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor VRTX freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.